Skip to Content
Merck
All Photos(1)

Key Documents

View All Documentation

SML2196

Sigma-Aldrich

Zotarolimus

≥95% (HPLC)

Synonym(s):

(42S)-42-Deoxy-42-(1H-tetrazol-1-yl)rapamycin, ABT-578

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C52H79N5O12
CAS Number:
221877-54-9
Molecular Weight:
966.21
MDL number:
MFCD09752954
UNSPSC Code:
51111800
NACRES:
NA.77

Assay

≥95% (HPLC)

form

powder

color

white to beige

solubility

DMSO: 2 mg/mL, clear

storage temp.

−20°C

SMILES string

C[C@H](CC[C@@H](C[C@H](OC)/C(C)=C/C=C/C=C/[C@H](C[C@H](C([C@H](OC)[C@@H](/C(C)=C/[C@@H](C)C1=O)O)=O)C)C)O2)[C@]2(O)C(C(N3CCCC[C@H]3C(O[C@H]([C@H](C)C[C@@H]4CC[C@H](N5N=NN=C5)[C@H](OC)C4)C1)=O)=O)=O

InChI

1S/C52H79N5O12/c1-31-16-12-11-13-17-32(2)43(65-8)28-39-21-19-37(7)52(64,69-39)49(61)50(62)56-23-15-14-18-41(56)51(63)68-44(34(4)26-38-20-22-40(45(27-38)66-9)57-30-53-54-55-57)29-42(58)33(3)25-36(6)47(60)48(67-10)46(59)35(5)24-31/h11-13,16-17,25,30-31,33-35,37-41,43-45,47-48,60,64H,14-15,18-24,26-29H2,1-10H3/b13-11+,16-12+,32-17+,36-25+/t31-,33-,34-,35-,37-,38+,39+,40+,41+,43+,44+,45-,47-,48+,52-/m1/s1

InChI key

CGTADGCBEXYWNE-JUKNQOCSSA-N

Biochem/physiol Actions

Zotarolimus (ABT-578) is a semi-synthetic rapamycin analog with immunosuppressant and anti-proliferative activity. It binds to the FKBP12 binding protein, which subsequently binds to the mammalian target of rapamycin (mTOR) causing cell cycle arrest in the G1 phase. Zotarolimus was designed to be used for delivery from drug-eluting coronary stents to prevent restenosis.
Zotarolimus is a second generation Drug Eluting Stent (DES).

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Keiichiro Miura et al.
Cardiovascular revascularization medicine : including molecular interventions, 16(6), 344-347 (2015-08-09)
Late and very late stent thrombosis after drug-eluting stent implantation is a major concern. The present study evaluated difference in the effects of sirolimus, paclitaxel and zotarolimus on endothelial cells. Mouse endothelial cells were seeded in a 6-well plate. Cells
Zotarolimus-eluting versus bare-metal stents in uncertain drug-eluting stent candidates
Valgimigli M, et al.
Journal of the American College of Cardiology, 65(8), 805-815 (2015)
Yuji Nishimoto et al.
Journal of cardiology, 70(3), 297-302 (2016-12-31)
First-generation drug-eluting stents (DES) have reduced short-term stent failure as compared to bare-metal stents due to the inhibition of neointima hyperplasia, but instead increased the risk of very-late stent failure. Although better outcomes have been reported for second-generation DES than
Fabrizio D'Ascenzo et al.
European heart journal, 38(42), 3160-3172 (2017-10-12)
The differential impact on ischaemic and bleeding events of the type of drug-eluting stent [durable polymer stents [DES] vs. biodegradable polymer stents vs. bioresorbable scaffolds (BRS)] and length of dual antiplatelet therapy (DAPT) remains to be defined. Randomized controlled trials

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service